KRAS and non-small cell lung carcinoma: [16] Similarly, a higher amount of cfDNA and KRAS-mutant cfDNA found in patients with advanced colorectal cancer treated with irinotecan and cetuximab and in patients with advanced NSCLC treated with carboplatin and vinorelbine was associated with a shorter progression-free survival and OS.